Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Can lipitor's effectiveness be affected by vitamin c?Have you asked your doctor about lipitor's diabetes risk?Any side effects from combining lipitor and low fat diet?What's vascepa's coverage under my plan?Can alcohol affect the effectiveness of cholesterol drugs?
See the DrugPatentWatch profile for sapropterin
How does sapropterin improve blood phenylalanine levels? Sapropterin is a synthetic form of tetrahydrobiopterin (BH4), the natural cofactor that activates phenylalanine hydroxylase (PAH). When patients carry residual PAH activity, sapropterin enhances the enzyme's function, lowering blood phenylalanine levels by 20-30% on average in responsive patients. [1] How do clinical trials measure sapropterin effectiveness? Clinical data show that 20-56% of PKU patients respond to sapropterin, depending on genotype and age. A randomized, double-blind study found 44% of patients treated with sapropterin at 20 mg/kg/day achieved at least a 30% drop in blood phenylalanine compared with 9% of placebo controls. [1] What factors determine who will respond to sapropterin? Patients with milder mutations that retain some PAH activity respond more often. Genetic testing and a four-week sapropterin trial can help identify responders. Non-responders gain no benefit and should continue strict dietary phenylalanine restriction. [2] When does the patent for sapropterin dihydrochloride expire? The primary compound patent for sapropterin dihydrochloride, owned by BioMarin, expires in 2025 in the US. [3]
Other Questions About Sapropterin :